|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
We used three mouse models of pathological ocular neovascularization: oxygen-induced retinopathy (a mouse model of ischemic retinopathies), laser-induced choroidal neovascularization, and a human VEGF transgenic mouse that overexpresses human VEGF specifically in photoreceptor cells and generates pathological neovascularization in the retina.
|
23195430 |
2013 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We suggest that "early worsening" of retinopathy results when diabetic patients with minimal to moderate retinopathy, whose retinal circulation and, hence, retinal oxygen supply is compromised, are placed on a "tight" glucose control regimen and their major remaining retinal energy source is reduced, with VEGF up-regulation as a compensatory mechanism.
|
21158590 |
2011 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We postulate that exogenous insulin could act synergistically with the vascular endothelial growth factor expressed by ischemic retina so as to trigger vascular proliferation and the worsening of diabetes retinopathy.
|
29017477 |
2017 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We hypothesised that the initial reduction of central macular thickness by ranibizumab should be maximum in severe diabetic retinopathy until the levels of VEGF decreases to the levels observed in eyes with mild retinopathy.MethodsConsecutive patients with centre-involving DMO (central subfield thickness (CSFT)>300 μm) who had three consecutive monthly ranibizumab injections followed by as needed therapy were included.
|
28452992 |
2017 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
We further show that prototype long-acting anti-VEGF drugs (LAVAs) that include this peptide attenuate VEGF-induced retinal changes in animal models of neovascular retinal disease ∼3-4-fold longer than unmodified drugs.
|
28332616 |
2017 |
|
Retinal Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We examined the possible association of the VEGF gene polymorphisms with diabetic nephropathy and retinopathy in type 2 diabetes patients.
|
17121786 |
2007 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Vitreal macrophages express vascular endothelial growth factor in oxygen-induced retinopathy.
|
11345346 |
2000 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Using RNA interference for targeted inhibition of VEGF isoforms in conjunction with IGF-I may be preferable for suppression of HREC overgrowth in vasoproliferative retinopathies such as ROP.
|
30093937 |
2018 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Transcription factors regulate GPR91-mediated expression of VEGF in hypoxia-induced retinopathy.
|
28374767 |
2017 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
To investigate whether vector-based HIF-1alpha -targeted shRNA expression system (pSUPER(siHIF-1alpha)) can inhibit HIF-1alpha and VEGF expression in vitro and suppress retinal neovascularization in the murine model of oxygen-induced retinopathy.
|
18853324 |
2008 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
To examine the three-dimensional morphology and vascular endothelial growth factor (VEGF) expression of skin microvasculature in patients with type 2 diabetes in relation to neuropathy, retinopathy and nephropathy.
|
30719863 |
2019 |
|
Retinal Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
To determine the potential genotype differences in the vascular endothelial growth factor (VEGF) gene in diabetic patients, which might explain the difference in terms of the development of clinical vascular complications: great vessels atherosclerosis vs. retinopathy.
|
22064697 |
2012 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
This study tested the hypothesis that endothelial cell-specific knockdown of VEGF receptor 2 (VEGFR2), or downstream STAT3, would inhibit VEGF-induced retinopathy without delaying physiologic retinal vascular development.
|
29730824 |
2018 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
This study suggests that melatonin may have potential value in the prevention and treatment of various retinal diseases associated with increase of VEGF, vascular leakage and angiogenesis.
|
27409056 |
2017 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
These observations indicated that the Wnt pathway/COX-2/VEGF axis plays a pathogenic role in retinopathy and represented novel therapeutic targets.
|
29158916 |
2017 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
These data explain the broad range of benefits obtained by VEGF suppression in patients with ischemic retinopathies, provide an important insight into the pathogenesis of RVO and diabetic retinopathy, and suggest that sustained suppression of VEGF early in the course of these diseases may prevent vessel closure, worsening ischemia, and disease progression.
|
28931763 |
2017 |
|
Retinal Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
These data demonstrate that multiple VEGFA variants are associated with the development of severe retinopathy in type 1 diabetes.
|
17513698 |
2007 |
|
Retinal Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The use of VEGF inhibitors for treatment of macular edema (due to radiation retinopathy) after irradiation of UM should be considered carefully, because of the possible adverse effects on residual UM cells.
|
23077404 |
2012 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The results suggest that the protective effect of TXF against cataract and retinopathy may be due to the anti-oxidative potential of TXF and its inhibiting effect on VEGF, ERK1/2, p38MAPK and aldose reductase.
|
31656158 |
2019 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The process of retinal neovascularization in ROP and in animal models of oxygen-induced retinopathy is complex, and involves angiogenic factors, such as vascular endothelial growth factor, and basement membrane components.
|
12930159 |
2003 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The peroxisome proliferator-activated receptor-gamma (PPARgamma) gene has been recently associated with type 2 diabetes, obesity and traits depending on VEGF expression (e.g. retinopathy).
|
15782399 |
2005 |
|
Retinal Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The newly developed anti-Tspan12 antibody has therapeutic effects in vasoproliferative retinopathy and can enhance the potency of existing anti- vascular endothelial growth factor agents.
|
28356444 |
2017 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The levels of VEGF were similar in patients with T1D and microvascular complications (microalbuminuria and retinopathy) when compared with patients without microvascular complications.
|
28421206 |
2017 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The extended retinopathy is concomitant with prolonged overexpression of retinal vascular endothelial growth factor in PWG pups.
|
21056995 |
2010 |
|
Retinal Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The beneficial effects of SkQ1 on retinopathy connected with normalization of expression of VEGF and PEDF in the retina of OXYS rats and depended on age of the animals and the stage of retinopathy.
|
21750722 |
2011 |